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ABSTRACT 
The aim of the current study was to test whether the grade group assessed in the index tumor 
nodule predicts biochemical recurrence after surgery. The study cohort series included 144 
consecutive patients treated by laparoscopic radical prostatectomy. The following parameters 
were evaluated in each case: type of radical prostatectomy (with/without lymphadenectomy), pT 
and pN status, histologic type of prostate carcinoma (acinar vs. mixed histology), surgical margin 
resection status, perineural invasion, lymphovascular invasion, biochemical recurrence status, 
presence of tertiary Gleason 5 pattern, and grade group that was assessed, both, in overall 
prostate cancer and in index (dominant) tumor nodule. Twenty patients (13.9%) experienced 
postoperative biochemical recurrence at a mean followup time of 12.2 months. The univariate 
survival analysis selected type of radical prostatectomy, histological subtype, lymphovascular 
invasion, AJCC pT and pN classification, tertiary Gleason 5 pattern, preoperative PSA level, and 
the grade group assessed in both the overall prostate and index tumor nodule as significant for 
biochemical recurrence-free survival. Type of radical prostatectomy (P=.020), histological 
subtype (P=.002), lymphovascular invasion (P=.023), tertiary Gleason pattern 5 (P=.016), and 
grade group classification in index tumor nodule (P≤.0001) were selected as independent 
predictors of biochemical recurrence-free survival. In conclusion, our results validate grade 
group in the index tumor nodule as an independent predictor of biochemical recurrence-free 
survival; thus, emphasizing the value of reporting grade group in index tumor nodule. The main 
limitation of our study is the relatively low number of cases in the current series, suggesting the 
need of large confirmatory studies. 
Keywords: Prostate cancer; radical prostatectomy; index tumor; index nodule; grade groups; 
biochemical recurrence 
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1. INTRODUCTION 
Gleason score is one of the most powerful pathological predictive factors of biochemical 
recurrence after radical prostatectomy [1-12]. To further improve Gleason score prognostic value 
in this setting, the WHO (2016) has incorporated the “grade group” system based on an earlier 
proposal by Jonathan I. Epstein and co-workers [13-34]. The “grade group” system has been 
validated in several large-scale studies, demonstrating increased predictive accuracy of both 
biochemical recurrence and mortality following radical prostatectomy [7-17, 19]. Conversely, 
most prostate cancers present as multifocal disease with two or more tumor nodules in the 
prostate gland [1-3, 34, 37]. Histologically, different tumor nodules in the same prostatectomy 
specimen often show different Gleason scores and, therefore, different grade groups [2, 3, 5, 7, 
11, 12, 21, 23, 24, 29]. To circumvent this issue, McNeal et al introduced the concept of 
“dominant/index tumor nodule” referring to a tumor nodule likely to harbor the most aggressive 
biological behavior among the multifocal tumor nodules within the prostate, which may dictate 
the overall biological behavior of the disease [25]. This controversial concept reflects the lack of 
consensus on the pathological parameters that defined the index tumor nodule in radical 
prostatectomy specimens [2, 3, 7, 12, 15, 18, 20, 21, 23, 26, 27, 30, 32, 35-41]. Current available 
data on the pathological features of index tumor nodule in multifocal prostate cancer is, however, 
quite limited. Likewise, according to most authorities, at present, index tumor nodule refers to 
the tumor nodule of the largest size in a multifocal disease [25-27, 30]. 
The concept of index tumor nodule has recently received considerable interest since it might 
also predict biochemical recurrence [1, 4, 6, 10, 20]. Reported experience also suggests that the 
index tumor nodule is not only the largest but also holds the highest Gleason score and is often 
the stage-determining tumor, as suggested by Karavitakis et al [26]. However, it is useful to note 
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that the index tumor nodule might not include the highest Gleason score, extraprostatic extension 
status, or the highest tumor volume in about 10% of cases [30]. In clinical terms, this concept is 
also appealing. Since the characteristics of the index tumor nodule may dictate the biologic 
behavior and the lethality of the tumor, a selective destruction of this lesion by means of focal 
therapy could potentially prevent or delay cancer progression [28, 31]. An additional advantage 
of the concept is the capability, by multiparametric MRI, to accurately identify the index tumor 
nodule in most patients, reportedly 9 in 10 patients, allowing targeting biopsies to identify more 
aggressive prostate cancer when multiparametric MRI guided [32, 36, 41-43]. Therefore, the 
potential of classifying prostate cancer in risk categories based in the index tumor nodule and its 
associated grade group category holds great promise and deserves to be substantiated.  
We hypothesized that grade group assessment in the index tumor nodule may better predict 
features of aggressive prostate cancer as compared with grade group assessed in the overall 
prostate. To answer this question, we have compared grade group in the index tumor lesion and 
in the overall prostate in a sequential cohort series of 144 laparoscopic radical prostatectomies in 
which followup was available. Other known prognostic parameters of prostate cancer also 
entered the study for comparison purposes or to assess the performance status of the current 
study. 
2. MATERIAL AND METHODS 
2.1. Patient cohort 
The study is based on 144 consecutive laparoscopic radical prostatectomies performed by two 
urologists experienced (>14 years) in laparoscopic prostatectomy and evaluated at our hospital 
between August 2012 and April 2016. None of the patients had androgen deprivation treatment 
or preoperative radiotherapy. Radical prostatectomy specimens were inked, sliced serially (at 3–
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5mm intervals), and examined by an experienced urologic pathologist (ALB). The entire prostate 
was embedded for all cases. We used the 2014 modified Gleason scoring system and the grade 
groups [5, 7, 11-15, 19, 34]. For the purpose of the study, grade group was retrospectively 
assigned to some earlier cases and AJCC/pTNM adjusted to 2017 8th edition [18]. 
The clinicopathological variables were prospectively collected and reviewed. Information 
included age (years) at surgery, Gleason score and grade group at radical prostatectomy, 
pathological stage category, and followup data on biochemical recurrence. Other analyzed 
parameters including lymphovascular or perineural invasion, extraprostatic extension, seminal 
vesicle invasion, and surgical margin status were assessed following reported criteria [2, 3, 9, 34, 
36, 41]. For the purpose of this study, the index tumor nodule (dominant nodule) was defined as 
the largest nodule measured linearly in mm. For the assessment, we measured the index nodule 
linearly in all related glass slides, and then the larger one was selected as the measurement of the 
index nodule lesion for that particular case. The vertical growth was not taken in consideration 
for the purpose of the study. The frequently observed infiltrative foci at the edge of the index 
nodule lesion, was included in the final measurement, even if it was discontinuous, if the 
pathologist was confident to consider related to it. Figure 1 A dedicated genitourinary pathologist 
signed-out all specimens. 
Patients were followed after surgery, according to the accepted guidelines, with PSA levels 
being typically checked at 3-month intervals for the first year and every 6 months for the 
subsequent 2 years. Biochemical recurrence following surgery was considered as PSA 
measurement >0.2 ng/mL [34]. The current project received the Institutional Review Board 
approval. 
2.2. Statistical analysis  
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Categorical variables were presented as frequencies and percentages, and were compared using 
the t test or chi-square test when appropriated. Continuous variables were expressed as mean ± 
standard deviation. The Kolmogorov–Smirnov test was used for normality analysis and 
nonparametric tests were used accordingly. The association between continuous variables and 
study variables was compared through the Mann–Whitney/Kruskal–Wallis. 
Survival curves (time to biochemical recurrence) were calculated using the product-limit 
method (Kaplan–Meier curves). Kaplan–Meier curves were constructed in order to demonstrate 
the probability of remaining free of biochemical recurrence as a function of time after radical 
prostatectomy. Statistically significant survival differences between groups were tested by 
applying a Log-rank test (Mantel–Cox). 
Cox proportional hazards regression analysis was performed to test the statistical 
independence with associated 95% confidence intervals between clinical preoperative and 
pathologic postoperative variables. For each variable analyzed, the assumption that no predictive 
value existed was rejected if P>.05. Statistical analysis was performed with all statistical 
analyses were performed with standard statistical software SPSS 17.0 version (SPSS, Inc., IL, 
USA). 
3. RESULTS  
Characteristics of 144 patients in the study are summarized in Table 1. The mean age at surgery 
was 61.38 years. The median preoperative PSA was 8.11 ng/mL. The patients were treated with 
radical prostatectomy alone (51%) or radical prostatectomy with extended lymph node dissection 
(49%). The mean followup for the entire cohort of patients was 27.9 months (12.8–60.7). During 
followup, 20 patients (13.9%) experienced biochemical recurrence. The mean age at time of 
biochemical recurrence was 63 years (50.5–74.6) with a median time to recurrence of 12.2 
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months (1.9–30.3). Mean index tumor nodule linear extension was about 19.3 mm (range, 4–44 
mm).  
Localized disease was seen in 57% of patients and locally advanced disease was observed in 
43%. Lymph node metastasis was seen in 11% of the 71 patients who underwent 
lymphadenectomy. Pure acinar adenocarcinoma was the most frequent histologic subtype (72%) 
but mixed acinar/non-acinar histology was seen in 28% of patients. Twenty percent of patients 
had positive resection margins. Perineural invasion and lymphovascular invasion were seen in 
89% and 5%, respectively. Tertiary Gleason pattern 5 (TGP5) was present in 2.1% of the cases.  
Preoperative PSA, treatment type, grade group classification both in the overall specimen and 
in the index tumor nodule, pT and pN status, histologic subtype, lymphovascular invasion, and 
TGP5 were all associated with biochemical recurrence in our cohort series (Table 2).  
The most common grade group was 2 (GG2), both in the index tumor nodule (71%) and in 
overall prostate cancer (80%). In general, the higher grade group was seen in index tumor 
nodule, not in overall prostate cancer: GG3 32% vs. 24%, GG4 8% vs. 6%, and GG5 3% vs. 
<1% (P<0.001). Table 3  
Grade groups in overall prostate cancer were associated with grade group in index tumor, 
treatment type, pT and pN status, histological subtype, lymphovascular invasion, and the 
presence of TGP5 (Table 3).  
The univariate survival analysis, selected treatment type, histological subtype, 
lymphovascular invasion, pT and pN status, the presence of TGP5, preoperative PSA, and grade 
groups determined in both the overall prostate cancer and the index tumor nodule were all 
associated with biochemical recurrence-free survival (Table 4; Figure 2). Cox multivariate 
analysis selected type of radical prostatectomy, histological subtype, lymphovascular invasion, 
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TGP5, and grade group assessed in the index tumor nodule as independent predictors of 
biochemical recurrence-free survival in our series (Table 4).  
4. DISCUSSION 
Different candidate pathologic parameters were evaluated in an attempt to predict biochemical 
recurrence following radical prostatectomy, Gleason score being considered one of the most 
powerful predictive factors [1-41]. To improve grading of prostate carcinoma and to lower the 
current limitations of the Gleason score, it has been internationally recommended to implement 
Epstein’s prognostic grade grouping system, recently endorsed by the WHO classification of 
genitourinary cancer under the designation of grade groups [14, 34]. Prognostic grade groups 
have been validated as predictive of biochemical recurrence, response to therapy, and cancer-
related mortality in several large-scale studies [7,14-17]. 
Contemporary defined index tumor nodule (larger prostate cancer nodule in multifocal 
disease) which frequently harbors the highest Gleason score has also been shown to be predictive 
of biochemical recurrence. It is, therefore, considered an important prognostic parameter in 
prostate cancer after radical prostatectomy [26-28, 30]. In fact, recent studies suggest that index 
tumor nodule can be identified in about 90% of radical prostatectomy samples and may be 
identified in 90% patients using multiparametric MRI and targeted biopsies [26-28, 30, 41-43]. 
Our study showed that identification of the grade group system in the index tumor nodule is 
feasible and of potential clinical relevance. In fact, the grade group was selected as a predictor of 
biochemical recurrence when assessed in overall prostate cancer, but turned out to be an 
independent predictor of biochemical recurrence-free survival when assessed in the index tumor 
nodule; an original contribution of our study emphasizing the effect of adding grade group to 
index tumor nodule since both parameters are considered powerful predictors of aggressive 
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features after radical prostatectomy. Hypothetically, the observed good correlation and adding 
effects of grade group in index tumor nodule, could give support to emerging clinically oriented 
proposals of using multiparametric MRI to summarize the aggressive features based on index 
tumor nodule features. This could lower unnecessary surgical procedures or provide a rational 
for focal therapy applications within the frame of grade group assessed in index tumor. Along 
this line, Radtke et al was able to identify over 90% of index tumor nodules in a series of radical 
prostatectomies aiming towards focal therapy and concluded that multiparametric MRI could 
identify 92% of index lesions [32].  Kasivisvanatha et al was able to identify higher grade tumors 
as compared to standard-biopsy, a fact that might be related a higher detection of index tumor 
lesions because of MRI guiding targets. In support of this is our finding of higher grade group 
categories in index tumor nodule, as compared with all prostate. [43]    
It is also important to bear in mind that our study included patients treated by laparoscopic 
radical prostatectomy only; these results might need to be validated for other surgical modalities.  
Our study also included the analysis of other known prognostic parameters in radical 
prostatectomy treated patients. Of relevance, as shown by the multivariate analysis, are type of 
radical prostatectomy (with/without lymphadenectomy), histological subtype (acinar vs. mixed), 
lymphovascular invasion, and the presence of TGP5. They were all independent predictors of 
biochemical recurrence-free survival. These results are not surprising and are in line with the 
current knowledge [1-41]. They most probably reflect an adequate therapy selection based on the 
current guidelines and validated nomograms. Therefore, our observation that the type of radical 
prostatectomy is an important predictor of biochemical recurrence is in agreement with the 
expected results since radical prostatectomy with extended lymphadenectomy is indicated in 
patients with more aggressive clinicopathologic features.  
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
11 
 
Another relevant observation in our series is that phenotypically mixed forms of prostate 
cancer beyond pure acinar predicts independently biochemical recurrence-free survival [7, 13, 
21, 33-35, 38-41]. This result concurs with previous observations regarding variants or 
morphologies associated with prostate cancer: that is ductal/intraductal/large cribriform 
morphologies, among others, are known to be associated with poor prognosis [7, 13, 21, 33-35, 
38-41]. Lymphovascular invasion is also known as an aggressive parameter in prostate cancer. A 
recently reported retrospective analysis of pathological and clinical data from 14,528 consecutive 
patients concluded that analysis of lymphatic invasion provides comparable prognostic 
information than lymph node analysis. Therefore, suggesting that even minimal involvement of 
the lymphatic system has a decisive prognostic impact in prostate cancer [9]. 
The presence of a TGP5, in patients with GS 7, was also associated with biochemical 
recurrence in our series and is in line with previous reports supporting higher grade elements, 
such as tertiary Gleason pattern in radical prostatectomy, have an adverse influence on prognosis 
[40]. Finally, our results agree with recent studies showing an excellent correlation between 
grade groups and different aggressive features in prostate cancer [7-19]. We also add further 
validation to the use of the prognostic grade group system in radical prostatectomy not only in 
large academic centers, but also in a comprehensive cancer center. Our study also found an 
independent predictive value of the grade group enriched index tumor nodule, a finding not 
previously reported and of relevance currently because of the increasing use of imaging methods 
such as multiparametric MRI. The limitations of our study include a limited followup of 28 
months and a relative low number of cases (n=144); therefore, our results should be interpreted 
with the necessary caution. 
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In conclusion, to our knowledge, this is the first study evaluating prostate cancer prognostic 
grade group in the index tumor nodule as predictor of biochemical recurrence after laparoscopic 
radical prostatectomy. Our results support reporting grade group system in the index tumor 
nodule since it better predicts biochemical recurrence than the grade group system assessed in 
the overall prostate cancer.  
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Table 1- Clinical and pathologic features of 144 patients who underwent  laparoscopic radical 
prostatectomy. 
Table 2 – Parameters associated with biochemical recurrence in a cohort series of 144 patients 
treated by laparoscopic radical prostatectomy. 
Table 3- Overall prostate grade-group compared to clinico-pathologic variables including the 
grade-group assessment in the index tumor.  
Table 4 - Univariate and multivariate analysis including separate models for grade group 
evaluation in the overall prostate (model 1) and index tumor lesi n (model 2). 
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Table 1. Clinical and pathologic features of 144 patients who underwent  
laparoscopic radical prostatectomy 
 
Mean age, year ±SD (range) 61.38±5.58 (47–75) 
Mean preoperative PSA ng/ ml (range) 8.11±4.91 (1–23) 
 N=144 % 
Treatment type   
Radical prostatectomy 73 50.7 
Radical prostatectomy with lymphadenectomy 71 49.3 
Prognostic grade group (Gleason score) overall prostate   
Grade group 1 (Gleason score ≤6) 19 13.2 
Grade group 2 (Gleason score 3+4=7) 80 55.6 
Grade group 3 (Gleason score 4+3=7) 35 24.3 
Grade group 4 (Gleason score 4+4=8) 9 6.3 
Grade group 5 (Gleason score 9–10) 1 0.7 
Prognostic grade group (Gleason score) (index tumor)   
Grade group 1 (Gleason score ≤6) 11 7.6 
Grade group 2 (Gleason score 3+4=7) 71 49.3 
Grade group 3 (Gleason score 4+3=7) 46 31.9 
Grade group 4 (Gleason score 8) 12 8.3 
Grade group 5 (Gleason scores 9–10) 4 2.8 
pT status (AJCC 2017)   
pT2 82 56.9 
pT3a 44 30.6 
pT3b 18 12.5 
pN status   
N0 63 43.8 
N1 8 5.6 
Nx 73 50.7 
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Histological subtype    
Acinar 104 72.2 
Mixed 40 27.8 
Surgical resection margin status    
R0 115 79.9 
R1 29 20.1 
Perineural invasion   
No 16 11.1 
Yes 128 88.9 
Lymphovascular invasion    
No 137 95.1 
Yes 7 4.9 
Biochemical recurrence   
No 124 86.1 
Yes 20 13.9 
TPG5   
No 141 97.9 
Yes 3 2.1 
AJCC, American Joint Committee on Cancer; PSA, serum prostate specific antigen; SD, standard  
deviation of the mean; TPG5, tertiary pattern of Gleason 5 
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Table 2. Parameters associated with biochemical recurrence in a cohort series  
of 144 patients treated by laparoscopic radical prostatectomy  
 
Value Biochemical Recurrence P Value* 
No Yes  
Age. n (mean±SD) 124 (61.37±5.56) 20 (61.40±5.86) 0.983** 
PSA. n (mean±SD) 120 (7.74±4.67) 20 (10.31±5.82) 0.030** 
Treatment type   0.001 
Radical prostatectomy 70 (56.5%) 3 (15.0%)  
Radical prostatectomy with lymphadenectomy 54 (43.5%) 17 (85.0%)  
Grade group (Gleason score), overall prostate  <0.001 
Grade group 1 (Gleason score ≤6) 19 (15.3%) 0 (0.0%)  
Grade group 2 (Gleason score 3+4=7) 75 (60.5%) 5 (25.0%)  
Grade group 3 (Gleason score 4+3=7) 24 (19.4%) 11 (55.0%)  
Grade group 4 (Gleason score 4+4=8) 6 (4.8%) 3 (15.0%)  
Grade group 5 (Gleason score 9–10) 0 (0.0%) 1 (5.0%)  
Grade group (Gleason score), index tumor  <0.001 
Grade group 1 (Gleason score ≤6) 11 (8.9%) 0 (0.0%)  
Grade group 2 (Gleason score 3+4=7) 69 (55.6%) 2 (10.0%)  
Grade group 3 (Gleason score 4+3=7) 37 (29.8%) 9 (45.0%)  
Grade group 4 (Gleason score 8) 7 (5.6%) 5 (25.0%)  
Grade group 5 (Gleason scores 9–10) 0 (0.0%) 4 (20.0%)  
pT status (AJCC 2017)   0.009 
pT2 76 (61.3%) 6 (30.0%)  
pT3a 36 (29.0%) 8 (40.0%)  
pT3b 12 (9.7%) 6 (30.0%)  
pN status   0.005 
N0 50 (40.3%) 13 (65.0%)  
N1 5 (4.0%) 3 (15.0%)  
Nx 69 (55.6%) 4 (20.0%)  
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Histological subtype    0.003 
Acinar 95 (76.6%) 9 (45.0%)  
Mixed 29 (23.4%) 11 (55.0%)  
Surgical resection margin status    0.236 
R0 101 (81.5%) 14 (70.0%)  
R1 23 (18.5%) 6 (30.0%)  
Perineural invasion   0.088 
No 16 (12.9%) 0 (0.0%)  
Yes 108 (87.1%) 20 (100.0%)  
Lymphovascular invasion    0.001 
No 121 (97.6%) 16 (80.0%)  
Yes 3 (2.4%) 4 (20.0%)  
TPG5   <0.001 
No 124 (100.0%) 17 (85.0%)  
Yes 0 (0.0%) 3 (15.0%)  
*Chi-square 
**Student t-test 
AJCC, American Joint Committee on Cancer; PSA, serum prostate specific antigen; SD, standard deviation of the mean; TPG5, 
tertiary pattern of Gleason 5 
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Table 3. Overall prostate grade-group compared to clinico-pathologic variables including the grade-
group assessment in index tumor lesion. 
 
 Overall Grade Group  P value*  
 Group 1 Group 2 Group 3 Group 4 Group 5  
Age. n (mean±SD) 19 60.32±7.8 80 61.1±5.9 35 62.2±.56 9 61.8±5.7 1 60.0±0.0 0.667** 
PSA. n (mean±SD) 17 6.5±3.6 79 7.4±4.6 34 9.9±6.3 9 8.0±3.5 1 6.0±0.0 0.097** 
Treatment type      <0.001 
Radical prostatectomy 13 (6.4%) 52 (65.0%) 6 (17.1%) 2 (22.2%) 0 (0.0%)  
Radical prostatectomy + 
lymphadenectomy 
6 (31.6%) 28 (35.0%) 29 (82.9%) 7 (77.8%) 1 (100.0%)  
Grade group (index tumor)      <0.001 
Grade group 1 (Gleason score ≤6) 11 (57.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)  
Grade group 2 (Gleason score 3+4=7) 8 (42.1%) 61 (76.3%) 2 (5.7%) 0 (0.0%) 0 (0.0%)  
Grade group 3 (Gleason score 4+3=7) 0 (0.0%) 17 (2.3%) 29 (82.9%) 0 (0.0%) 0 (0.0%)  
Grade group 4 (Gleason score 8) 0 (0.0%) 2 (2.5%) 2 (5.7%) 8 (88.9%) 0 (0.0%)  
Grade group 5 (Gleason scores 9–10) 0 (0.0%) 0 (0.0%) 2 (5.7%) 1 (11.1%) 1 (100.0%)  
pT status (AJCC 2017)      <0.001 
pT2 15 (78.9%) 55 (68.8%) 11 (31.4%) 1 (11.1%) 0 (0.0%)  
pT3a 4 (21.1%) 20 (25.0%) 13 (37.1%) 6 (66.7%) 1 (100.0%)  
pT3b 0 (0.0%) 4 (21.1%) 11 (31.4%) 2 (22.2%) 0 (0.0%)  
pN      <0.001 
N0 7 (36.8%) 26 (32.5%) 25 (71.4%) 4 (44.4%) 1 (100.0%)  
N1 0 (0.0%) 2 (2.5%) 4 (11.4%) 2 (22.2%) 0 (0.0%)  
Nx 12 (63.2%) 52 (65.0%) 6 (17.1%) 3 (33.3%) 0 (0.0%)  
Histological subtype       0.021 
Acinar 19 (100.0%) 58 (72.5%) 21 (60.0%) 5 (55.6%) 1 (100.0%)  
Mixed 0 (0.0%) 22 (27.5%) 14 (40.0%) 4 (44.4%) 0 (0.0%)  
Margin status       0.374 
R0 15 (78.9%) 67 (83.8%) 24 (68.6%) 8 (88.9%) 1 (100.0%)  
R1 4 (21.1%) 13 (16.3%) 11 (31.4%) 1 (11.1%) 0 (0.0%)  
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Perineural invasion      0.307 
No 5 (26.3%) 9 (11.3%) 2 (5.7%) 0 (0.0%) 0 (0.0%)  
Yes 14 (73.7%) 71 (88.8%) 33 (94.3%) 9 (100.0%) 1 (100.0%)  
Lymphovascular invasion       <0.001 
No 18 (94.7%) 79 (98.8%) 31 (88.6%) 9 (100.0%) 0 (0.0%)  
Yes 1 (5.3%) 1 (1.3%) 4 (11.4%) 0 (0.0%) 1 (100.0%)  
TPG5       0.049 
No 19 (100.0%) 80 (100.0%) 32 (91.4%) 9 (100.0%) 1 (100.0%)  
Yes 0 (0.0%) 0 (0.0%) 3 (8.6%) 0 (0.0%) 0 (0.0%)  
*Chi-square 
**ANOVA test 
AJCC, American Joint Committee on Cancer; PSA, serum preoperative prostate specific antigen; TPG5, tertiary pattern of 
Gleason 5 
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Table 4. Univariate and multivariate analysis including separate models for grade group evaluation in 
the overall prostate (model 1) and index tumor lesion (model 2). 
UNIVARIATE SURVIVAL ANALYSIS P Value HR 95.0% CI 
Treatment type RP vs. RP+LND 0.010 5.119 1.489 17.593 
Histological subtype 0.001 5.022 1.986 12.700 
Margin status 0.208 1.852 0.710 4.835 
Perineural invasion 0.307 24.20 0.053 10981.062 
Lymphovascular invasion 0.001 5.997 1.996 18.016 
AJCC classification  
pT2 vs pT3 0.020 3.128 1.201 8.143 
pN     
N0  1.00 (Ref)   
N1 0.163 2.456 0.700  8.608 
Nx 0.045 0.315 0.102  0.969 
TPG5  0.0001 10.256 2.957 35.579 
PSA (pre-surgery)  0.032 1.081 1.007 1.161 
Age at diagnosis  0.863 0.993 0.918 1.074 
Univariate analysis for grade group in overall prostate (model 1) 
Grade group 1 0.966 0.000   
Grade group 2  1.00 (Ref)   
Grade group 3 0.006 4.461 1.551  12.829 
Grade group 4 0.038 4.731 1.101  20.363 
Grade group 5 0.004 23.628 2.721  205.129 
Univariate analysis for grade group in index tumor (model 2) 
Grade group 1  0.9623 0.000   
Grade group 2   1.00 (Ref)   
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Grade group 3  0.015 6.671 1.451  30.671 
Grade group 4  0.002 14.880 2.822 78.463 
Grade group 5  <0.000 62.499 11.230  347.837 
MULTIVARIATE SURVIVAL ANALYSIS 
Treatment type: RP vs. RP+LND 0.020 4.439 1.277   15.423 
Histological subtype: Acinar vs. mixed 0.002 2.133 1.3262  3.431 
Lymphovascular invasion 0.023 3.795 1.208   11.919 
TPG5  0.016 4.819 1.358  17.102 
Grade group in index tumor (model 2) 
Grade group 2   1.00 (Ref)   
Grade group 3  0.044 5.005 1.048  23.899 
Grade group 4  0.007 10.858 1.966   59.953 
Grade group 5  <0.000 40.484 6.9756  234.951 
AJCC, American Joint Committee on Cancer; CI, confidence interval; HR, hazard ratio; LND, lymphadenectomy; PSA, serum 
prostate specific antigen; RP, radical prostatectomy; TPG5, tertiary pattern of Gleason 5  
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Figure 1 – Gross picture of an index tumor lession in the prostate (right) and an addition smaller 
tumor (left) (laparoscopic radical prostatectomy; case# 16H01051) 
Figure 2 – Univariated survival analysis with Kaplan-Meier plots and log-rank analysis 
indicating biochemical recurrence-free survival differences of patients after laparoscopic radical 
prostatectomy. Cox’s multivariate analysis selected these parameters as independent predictors 
(A, B, C, D, E). Figure E refers to the index tumour.  RP: Radical Prostatectomy; RP+LN: 
Radical prostatectomy plus lymphadenectomy (PR+LN).Lymphovascular invasion presence 
(LVI+) or absent (LVI). Tertiary Gleason pattern 5 present (TG5+) or absent (TG5-). GG1 to 5: 
Grade-group 1 to 5.  
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Highlights 
Type of radical prostatectomy (with or without) lymph node , histological subtype (acinar vs. 
mixed) of prostate adenocarcinoma, lymphovascular invasion, tertiary Gleason pattern 5, and  
grade group assessment in the index tumor nodule are  independent predictors of biochemical 
recurrence-free survival after radical prostatectomy. 
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